Osteoporosis: From early fracture prevention to better bone health with strontium ranelate

Rheumatology (United Kingdom)

Volumn 48, Issue SUPPL.4, 2009, Pages

  Cortet, Bernard ^a  

^a Rheumatology Department   (France)

Author keywords

Anti fracture efficacy; Hip fracture; Non vertebral fracture; Osteoporosis; Strontium ranelate; Vertebral fracture

Indexed keywords

BONE DENSITY CONSERVATION AGENT; ORGANOMETALLIC COMPOUND; STRONTIUM RANELATE; THIOPHENE DERIVATIVE;

AGED; BONE DENSITY; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; MIDDLE AGED; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES;

EID: 84864293913     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep275     Document Type: Article

References (56)

1. Reginster J-Y, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38 (Suppl. 1):S4-S9.
2. Cooper C, Campion G, Melton LJ 3rd.. Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 1992;2:285-9.
3. Burge R, Dawson-Hughes B, Solomon DH et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75.
4. Gullberg B, Johnell O, Kanis JA. Worldwide projections for hip fracture. Osteoporos Int 1997;7:407-13.
5. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002;50:1644-50.
6. Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 1990;45:M101-7.
7. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton III LJ. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5.
8. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16 (Suppl. 2):S3-7.
9. Delmas PD, van de Langerijt L, Watts NB et al. IMPACT Study Group. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 2005;20:557-63.
10. Klotzbuecher CM, Ross PD, Landsman PB, Abbott III TA, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39.
11. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61.
12. Sanders KM, Nicholson GC, Watts JJ et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006;38:694-700.
13. Osteoporosis. www.patient.co.uk/showdoc/40001187 (3 October 2008, date last accessed).
14. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med 2004;350:459-68.
15. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90: 2816-22.
16. Roux C. Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis. Rheumatology 2008;47(Suppl. 4):20-22.
17. Burlet N, Reginster J-Y. Strontium ranelate: the first dual acting treatment for postmenpausal osteoporosis. Clin Orthop Relat Res 2006;443:55-60.
18. Black DM, Cummings SR, Karpf DB et al., for the Fracture Intervention Trial Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
19. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
20. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc 1999;282:1344-52.
21. Reginster JY, Minne HW, Sorensen OH et al. Randomized trail of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
22. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
23. Chesnut CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
24. Cranney A, Tugwell P, Zyraruk N et al. Meta-analysis of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524-8.
25. Delmas PD, Genant HK, Crans GG et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-32.
26. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
27. Meunier PJ, Slosman D, Delmas PD et al. Strontium ranelate: dose-dependent effects in established post menopausal vertebral osteoporosis. The STRATOS 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6.
28. Reginster JY, Deroisy R, Dougados M et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, doseranging, placebo-controlled PREVOS trial. Osteoporos Int 2002;13:925-31.
29. Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72-5.
30. Melton 3rd LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
31. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996;312:1254-9.
32. Li Z, Chines AA, Meredith MP. Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuronal Interact 2004;4: 64-74.
33. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with metaanalyses. J Bone Miner Res 2004;19:330-7.
34. Protelos Summary of Product Characteristics. London, UK: EMEA; September 2004.
35. Bruyere O, Roux C, Detilleux J et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007;92:3076-81.
36. Watts NB, Cooper C, Lindsay R et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004;7:255-61.
37. Kanis JA, Burlet N, Cooper C et al. European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
38. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10.
39. Bruyere O, Roux C, Badurski J et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 2007;12:3041-5.
40. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 2004; 34:599-604.
41. Roux C, Reginster J-Y, Fechtenbaum J et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006;21:536-42.
42. Siris ES, Chen YT, Abbott TA et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-12.
43. Sanders KM, Nicholson GC, Watts JJ et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost effective? Bone 2006;38:694-700.
44. Kanis JA, Johnell O, Black DM et al. Effects of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial. Bone 2008;33:293-300.
45. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005;80:343-9.
46. Heaney RP, Zizic TM, Fogelman I. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002;13:501-5.
47. Seeman E, Devogelaer J-P, Lorenc R et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopaenia. J Bone Miner Res 2008;23:433-8.
48. van Staa TP, Leufkens HGM, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 2002;13:624-9.
49. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82.
50. Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. J Am Med Assoc 2003;290:1729-38.
51. Marcus R, Wang O, Satterwhite J et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18:18-23.
52. Kanis JA, Barton IP, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 2005;16: 475-82.
53. Roux C, Fechtenbaum J, Kolta S et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2008;67:1736-8.
54. Nevitt MC, Ettinger B, Black DM et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800.
55. Marquis P, De La Loge C, Diaz-Curiel M et al. Beneficial effects of strontium ranelate on the quality of life in patients with vertebral osteoporosis (SOTI study). Osteoporos Int 2005;16(Suppl. 3):S54.
56. Boonen S. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review. Curr Opin Rheumatol 2006;18(Suppl. 1):S21-7.